logo
  

Valero Energy Q2 Profit Tops Estimates - Quick Facts

Valero Energy Corp. (VLO) reported second-quarter net income from continuing operations attributable to stockholders of $1.4 billion, or $2.66 per share, compared to $651 million, or $1.22 per share, in the second quarter of 2014.

On average, 19 analysts polled by Thomson Reuters expected the company to report profit per share of $2.42 for the quarter. Analysts' estimates typically exclude special items.

Operating revenues were $25.12 billion compared to $34.91 billion, a year ago. Analysts expected revenue of $19.91 billion for the quarter.

"After completing a heavy planned maintenance period in the prior quarter, our refineries were ready and available to respond to improving market conditions in the second quarter," said Joe Gorder, Valero Chairman, President and CEO. Valero said the company is on track to complete its goal of $1 billion of drop-down transactions to VLP in 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT